Raloxifene combined with calcium phosphate cement for repair of rabbit mandibular defects

doi:10.3969/j.issn.2095-4344.2014.25.010

Abstract

Abstract:

BACKGROUND: Raloxifene is the third generation of selective estrogen receptor modulators, which can decrease bone loss, increase bone mineral content, and reduce fracture risk.
OBJECTIVE: To study the effects of raloxifene combined with self-setting calcium phosphate cement on the repair of rabbit mandibular defects.
METHODS: Totally 36 New Zealand white rabbits were selected to prepare 8 mm×4 mm×3 mm mandibular defect models, and then randomized equally into experimental group (raloxifene, 7.5 mg/kg per day, combined with self-setting calcium phosphate cement), drug group (raloxifene, 7.5 mg/kg per day), artificial bone group (self-setting calcium phosphate cement). Rabbits were sacrificed 4, 8 and 12 weeks later, respectively, for measurement of bone morphogenetic protein 2 using immunohistochemistry method and transforming growth factor β using a laser scanning confocal microscope.
RESULTS AND CONCLUSION: After 4 and 8 weeks, the expression of bone morphogenetic protein 2 was obviously higher in the experimental group than the drug and artificial bone groups; after 12 weeks, bone remodeling was basically complete in the experimental group, and the expression of bone morphogenetic protein 2 became lower than that in the other two groups. The expression of transforming growth factor β in the experimental group was gradually increased and reached the peak at 8 weeks, while in the drug and artificial bone groups, the expression of transforming growth factor β exhibited an increasing trend within 4-12 weeks, which was close to the peak. These findings suggest that raloxifene can promote early expression of bone morphogenetic proteins and early callus formation as well as accelerate the repair of bone defects with calcium phosphate cement.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

全文链接：

Key words: biocompatible materials, calcium phosphates, raloxifene, bone morphogenetic proteins, transforming growth factor beta

CLC Number:

R318

Guan Jian, Xu Feng. Raloxifene combined with calcium phosphate cement for repair of rabbit mandibular defects[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(25): 3993-3997.

Figures/Tables 2

References

[1] 唐超,张伯科,周琦,等.雷洛昔芬对蛋白尿慢性肾纤维化大鼠肾脏的保护作用[J].安徽医科大学学报,2010,45(3):363.
[2] 路会侠,李绍波.雷洛昔芬对去势大鼠骨密度IL-6的影响[J].海南医学,2008,19(6):111.
[3] 李勇,李善昌,宁尚波,等.柚皮甙复合自固化磷酸钙支架材料修复骨缺损的实验研究[J].口腔医学研究,2011,27(12):1039-1041.
[4] 苗波,隋长德,李慕勤,等.羟基磷灰石/骨碎补复合材料修复骨缺损的实验研究[J]黑龙江医药科学,2009,32(2):3-4.
[5] Parisien M,Silverberg SJ,Shane E,et al.The histomorphometry of bone in primary hyperparathyroidism: priservation of canellous bone structure.J Clin Endocrinol Metab.1999;70(4):930-938.
[6] 朱小峰,林李嵩,邱宇.雷洛昔芬对骨质疏松大鼠颅骨缺损修复的影响[J].河南河面外科,2010,16(6):39-44.
[7] Agrillo A,Sassano P,Mustazza MC,et al.Complex-type penertrating injuries of craniomaxillofacial region.J Craniofac Surg.2006;17(3):442-446.
[8] 贝朝涌,林卓峰,杨志,等.NGF对骨折愈合影响的研究[J].中国修复重建外科杂志,2009,23(5):570-576.
[9] Lawrence H,Bannister S,Martin M.Berry格式解破学[M].沈阳:辽宁教育出版社,1999:483-484.
[10] Silverberg SJ,Shane E,Cruz L,et al.Skeletal disease in primary hyperparathyoidism.J Bone Miner Res.2001;4:289-291.
[11] Matsumori H,Hattori K,Ohgushi H,et al.Raloxifene:its ossification-promoting effect on female mesenchymal stem cells.J Orthop Sci.2009;14(5):640-645.
[12] Parisien M,Cosman F,Mellish RW,et al.Bone structure in postmenopausal hyperparathyroid,osteoporotic,and normal women.J Bone Miner Res.2003;10:1393-1399.
[13] 邓慧鑫,关键,朱丽萍,张国梁,等.成骨细胞/CPC复合材料对兔下颌骨缺损的影响[J].黑龙江医疗科学,2010,33(3):919-921.
[14] 张滨,闫景龙,夏景君,等.骨形态发生蛋白在微小颗粒骨诱导成骨过程中的表达[J].中国矫形外科杂志,2004,12(16)12:48-49.
[15] Body JJ,Sternon J.Raloxifene (Celvista, Evista).Rev Med Brux.2000;21(1):35-41.
[16] Sato M,Bryant HU,Iversen P,et al.Advantages of raloxifene over alendronate or estrogen on nonreproductive tissues in the long-term dosing of ovariectomized rats.J Pharmacol Exp Ther.1996;279:298-305.
[17] Black LJ,Sato M,Rowley ER,et al.Raloxifene (LY139481HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.J Clin Invest.1994;93:63-66.
[18] Lane NE,Sanchez S,Modin GW,et al.Parathyroid hormone treament can reverse corticosteroid-induced osteoporosis: results of a randomized controlled clinical trial.Clin Invest. 1998;102:1627-1633.
[19] Nakaoka D,Sugimoto T,Kobayashi T,et al.Prediction of bone mass change after parathyroidectomy in patients with primary hyperparathyoidism.Clin Edocrinol Metab.2000;85:1901-1907.
[20] Cosman F,Nieves J,Woelfert L,et al.Parathyroid hormone added to established hormone therapy:effects on vertebral fractrue and maintenance of bone mass after parathyroid hormone withdrawal.Bone Miner Res.2001;16:925-931.
[21] 毕崇萍,张绍芬,金慰芳.雷洛昔芬对大鼠成骨细胞的增殖、分化和矿化的影响[J].老年医学与保健,2007,13(4):223-222.
[22] Jordan VC.A currentview of tamoxifen for the treatment and prevention of breastcancer.Br J Pharmacol.1993;110(2): 507-517.
[23] Martino S,Costantion J,Mcnabb M,et al.The role of selective estrogen receptor modulators in the prevention of breast cancer:comparison of the clinical trials.Oncologist. 2004;9(2): 116-125.
[24] 姜荷艳,王锐,孙立军.雷洛昔芬对绝经后骨质疏松症的疗效观察[J].实用预防医学,2010,17(3):551-552.
[25] 王文波,陈中伟,陈统一.自固化磷酸钙人工骨的最新研究进展[J].生物医学工程杂志,2000,17(1):80-83.
[26] 曾中华,余黎,龚玲玲,等.骨折愈合过程中BMP-2和VEGF的表达[J].武汉大学学报:医学版,2005,26(4):467-469.
[27] Athanasopoulos AN,Schneider D,Keiper T,et al.Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activties in endothelial cells and promotes fracture healing.Biol Chem. 2007;282(37):26746-26753.
[28] Kaps C,Bramlage C,Smolian H,et al.Bone morphogenetic proteins promote cartilage differentiation and protect engineered artificial cartilage from fibroblast invasion and destruction.Arthritis Rheum.2002;46(1):149-162.
[29] Yamaguchi A,Katagiri T,Ikeda T,et al.Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro.Cell Biol.1991;113(3):681-687.
[30] 张永刚,卢世璧,王继芳,等.骨形态发生蛋白和转化生长因子-β及碱性成纤维细胞生长因子在骨折修复中的表达[J].中华创伤杂志,2000,16(3):170-172.
[31] 郭书权,许建中.BMP-2诱导成骨及传送的研究进展[J].第三军医大学学报,2005,27(16):1707-1710.
[32] Yang L,Zhang KH,Zhu XF,et al.Effects of benefiting bone capsule on expression of bone morphogenetic protein-2 in bone tissue of theovariectomixed rats.Zhongguo Linchuang Kangfu.2006;10(3):190-192.
[33] Szczesny G. Growth factors in bone.Int Orthop.1998;22(6): 410-416.
[34] Chen D,Harris MA,Rossini G,et al.Bone morphoge-netic protein2(BMP-2)enhances BMP-3,BMP-4,and bone cell differentiation marker henes expression during the induction of mine ralizal bone mat rix formation in cultures of fetal rat calvarial osteoblasts.Calcif Tissue Int.1997;60(3):283-290.
[35] 胡德志,付刚.骨形态发生蛋白2(BMP-2)的研究进展[J].中医正骨,1998,10(1):47-49.
[36] Beck LS,Amento EP,Xu Y,et al.TGF-beta 1 induces bone closure of skull defects: temporal dynamics of bone formation in defects exposed to rhTGF-beta 1.J Bone Miner Res.1993;8:753.
[37] 卢翔,陈江宁,张峻峰.雷洛昔芬通过促进一氧化氮释放诱导脂肪干细胞向成骨细胞分化[J].中国药理学通报,2011,27(1):24.
[38] Tsuji K,Cox K,Bandyopadhyay A,et al.BMP4 is dispensable for skeletogenesis and fracture healing in the limb.J Bone Join Surg Am.2008;90(suppl.1):14.
[39] Sheehan JP,Sheehan JM,Sheehan JMH,et al.The safety and utility of recombinant human bone morphogenetic protein-2 for cranial procedures in a nonhuman primate model.J Neursurg.2003;98(1):125-130.
[40] 杨济洲,徐林,穆岭.骨痛膏促进家兔骨愈合的实验研究[J].吉林中医药,2010,5(30):447-449.